OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients

The Journal of Headache and Pain

Research Article

Susie Lagrata¹  Sarah Miller¹  Manjit S Matharu¹  Fernando Correia² 

[1] Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery Queen Square, WC1N 3BG, London, UK;Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery Queen Square, WC1N 3BG, London, UK;Department of Neurology, Centro Hospitalar do Porto, Oporto, Portugal;

关键词: Botulinum toxin-A;    Hemicrania continua;    Treatment;    Indomethacin;   

DOI  :  10.1186/s10194-015-0502-z

 received in 2015-01-20, accepted in 2015-02-16,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundHemicrania continua is a strictly unilateral, continuous headache, typically mild to moderate in severity, with severe exacerbations commonly accompanied by cranial autonomic features and migrainous symptoms. It is exquisitely responsive to Indomethacin. However, some patients cannot tolerate treatment, often due to gastrointestinal side effects. Therapeutic alternatives are limited and controlled evidence lacking.MethodsWe present our experience of nine patients treated with OnabotulinumtoxinA for hemicrania continua. All patients were injected using the PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) protocol for migraine.ResultsFive of nine patients demonstrated a 50% or more reduction in moderate to severe headache days with OnabotulinumtoxinA with a median reduction in moderate to severe headache days of 80%. Patient estimate of response was 80% or more in five subjects. The median and mean duration of response in the five responders was 11 and 12 weeks (range 6–20 weeks). Improvements were also seen in headache-associated disabilityConclusionsOnabotulinumtoxinA adds a potential option to the limited therapeutic alternatives available in hemicrania continua.

【 授权许可】

Unknown   
© Miller et al.; licensee Springer. 2015. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.